Saito M, Miura T, Furukawa K, Kato H
Department of Chest Surgery, Tokyo Medical University, Kasumigaura Hospital, Ibaraki, Japan.
Nihon Geka Gakkai Zasshi. 2001 Jul;102(7):511-6.
The Standard surgical treatment for stage I, II, and IIIa non-small cell lung cancer (NSCLC) is lobectomy with systemic mediastinal lymph node dissection. More than 50% of our series of 220 patients with cN2 disease were classified as pN0-1. The postoperative 5-year survival rate of patients with cN2 disease was 36%, and that of those with cN2-pN2 disease was 18%. Tumor cell type, surgical technique, or site of tumor had no prognostic significance, although pN, cT, and number of N2 sites were of prognostic significance. We conclude that the indications for surgery are T1-2 N2 disease with a single N2 site.
I、II和IIIa期非小细胞肺癌（NSCLC）的标准外科治疗方法是肺叶切除术并进行系统性纵隔淋巴结清扫。在我们收治的220例cN2期疾病患者中，超过50%被归类为pN0-1。cN2期疾病患者的术后5年生存率为36%，而cN2-pN2期疾病患者的术后5年生存率为18%。肿瘤细胞类型、手术技术或肿瘤部位无预后意义，尽管pN、cT和N2部位数量具有预后意义。我们得出结论，手术适应证为单个N2部位的T1-2 N2期疾病。
